Abstract:Epidemiology is the study of how disease is distributed in populations and the factors that influence or determine this distribution. Clinical epidemiology denotes the application of epidemiologic methods to questions relevant to patient care and provides a highly useful set of principles and methods for the design and conduct of quantitative clinical research. Validly analyzing, correctly reporting, and successfully interpreting the findings of a clinical research study often require an understanding of the epidemiologic terms and measures that describe the patterns of association between the exposure of interest (treatment or intervention) and a health outcome (disease). This statistical tutorial thus discusses selected fundamental epidemiologic concepts and terminology that are applicable to clinical research. Incidence is the occurrence of a health outcome during a specific time period. Prevalence is the existence of a health outcome during a specific time period. The relative risk can be defined as the probability of the outcome of interest (eg, developing the disease) among exposed individuals compared to the probability of the same event in nonexposed individuals. The odds ratio is a measure of risk that compares the frequency of exposure to a putative causal factor in the individuals with the health outcome (cases) versus those individuals without the health outcome (controls). Factors that are associated with both the exposure and the outcome of interest need to be considered to avoid bias in your estimate of risk. Because it takes into consideration the contribution of extraneous variables (confounders), the adjusted odds ratio provides a more valid estimation of the association between the exposure and the health outcome and thus is the preferably reported measure. The odds ratio closely approximates the risk ratio in a cohort study or a randomized controlled trial when the outcome of interest does not occur frequently (<10%). The editors, reviewers, authors, and readers of journal articles should be aware of and make the key distinction between the absolute risk reduction and the relative risk reduction. In assessing the findings of a clinical study, the investigators, reviewers, and readers must determine if the findings are not only statistically significant, but also clinically meaningful. Furthermore, in deciding on the merits of a new medication or other therapeutic intervention, the clinician must balance the benefits versus the adverse effects in individual patients. The number needed to treat and the number needed to harm can provide this needed additional insight and perspective.

Preventable fraction in the context of disease progression

Relative risks, the probability of necessity, and attributable fractions

The population-attributable fraction for time-dependent exposures using dynamic prediction and landmarking

PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS

The population-attributable fraction for time-dependent exposures and competing risks - A discussion on estimands

Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials

Optimal survival analyses with prevalent and incident patients

Identifying Principal Stratum Causal Effects Conditional on a Post-treatment Intermediate Response

Modelling the impact of precaution on disease dynamics and its evolution

The Predictive Individual Effect for Survival Data

Optimal stratification in outcome prediction using baseline information.

Randomization for the susceptibility effect of an infectious disease intervention

Proportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors

Reevaluating the fraction of cancer attributable to excess weight: overcoming the hidden impact of prediagnostic weight loss

Estimation of trajectory of protective efficacy in infectious disease prevention trials using recurrent event times

Fundamental Epidemiology Terminology and Measures: It Really Is All in the Name

Risk projection for time-to-event outcome from population-based case–control studies leveraging summary statistics from the target population

Proportion of treatment effect explained: An overview of interpretations

Re: Bias in Calculation of Attributable Fractions Using Relative Risks from Nonsmokers Only

Risk Projection for Time-to-Event Outcome Leveraging Summary Statistics With Source Individual-Level Data